EAU 2023

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to an abstract session addressing cell biology, novel biomarkers, and trials in non-muscle invasive bladder cancer. Professor Lars Dyrskjøt presented the results of a study evaluating immunological changes following blue light cystoscopy with hexaminolevulinate in bladder cancer.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to an abstract session of studies addressing the treatment of non-muscle invasive bladder cancer (NMIBC). Dr. Siamak Daneshmand presented the results of a study evaluating the performance of blue light cystoscopy in delaying time to recurrence in patients with NMIBC, within the context of a real-world setting.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a rapid-fire debate session addressing common problems and controversies in bladder cancer, chaired by Dr. Ashish Kamat.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a rapid-fire debates session addressing common problems and controversies in bladder cancer, chaired by Dr. Ashish Kamat. Following a case presentation by Dr. Jørgen Bjerggaard Jensen, Dr. Param Mariappan was tasked with debating against prostate-sparing radical cystectomy in men and reproductive organ-sparing in women as safe options for patients with muscle-invasive bladder cancer. Conversely, Dr. Maria Carmin Mir was tasked with debating in favor of such approaches.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a rapid-fire debate session addressing common problems and controversies in bladder cancer, chaired by Dr. Ashish Kamat.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a session addressing precision medicine in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Bertrand Tombal delivered a state-of-the-art lecture discussing the appropriate timing and patient selection for PARP inhibitor use.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a session addressing precision medicine in patients with metastatic castrate-resistant prostate cancer (mCRPC). Professor Thomas Steuber delivered a state-of-the-art lecture addressing optimal treatment sequencing in the area of triplet therapies for hormone-sensitive prostate cancer.

(UroToday.com) The 2023 EAU annual meeting included a session discussing clinically meaningful questions in the management of advanced, hormone-sensitive prostate cancer, featuring a debate regarding the added value of docetaxel in combination with ADT and ARPI for the treatment of mHSPC.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a session addressing precision medicine in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Stefano Fanti delivered a state-of-the-art lecture discussing best predictive factors for successful treatment with LuPSMA.

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a session addressing precision medicine in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Christopher Evans delivered a state-of-the-art lecture discussing how and when to sequence with molecular testing in patients with mCRPC.

(UroToday.com) The 2023 EAU annual meeting included a joint session of the EAU and the Advanced Prostate Cancer Consensus, featuring a presentation by Dr. Bertrand Tombal (after Dr. Van Oort was unable to present at the last minute) discussing how among patients with high-risk localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT, we should be treating these patients with surgery +/- radiotherapy +/- systemic treatment.

(UroToday.com) The 2023 EAU annual meeting included a session discussing clinically meaningful questions in the management of advanced, hormone-sensitive prostate cancer, featuring a debate of treatment for low-volume disease at conventional imaging, with 5 bone metastases at PSMA PET/CT.

(UroToday.com) The 2023 EAU annual meeting included a joint session of the EAU and the Advanced Prostate Cancer Consensus, featuring a presentation by Dr. Thomas Zilli discussing how among patients with high-risk localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT, we should be treating these patients with radiotherapy +/- systemic treatment. Dr. Zilli started his presentation by highlighting that the addition of local radiotherapy to continuous androgen suppression improves overall survival in high-risk or locally-advanced prostate cancer compared to systemic therapy alone. This is based off of data from the SPCG-7 trial¹ and the NCIC/MRC trial:²

(UroToday.com) The 2023 EAU annual meeting included a joint session of the EAU and the Advanced Prostate Cancer Consensus, featuring a presentation by Dr. Eva Comperat discussing how among patients with high-risk localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT, subtypes of prostate cancer can change our management. For patients with rare subtypes, Dr. Comperat notes that Gleason score is not sufficient for risk stratification. For acinar prostate cancer, different histological patterns include (i) atrophic acinar adenocarcinoma, (ii) pseudohyperplastic acinar adenocarcinoma, (iii) microcystic acinar adenocarcinoma, (iv) foamy gland acinar adenocarcinoma, and (v) mucinous (colloid) acinar adenocarcinoma. The specific subtypes (morphologically distinct and have prognostic significance) for acinar prostate cancer include:

(UroToday.com) The 2023 EAU annual meeting included a joint session of the EAU and the Advanced Prostate Cancer Consensus, featuring a presentation by Dr. Maria De Santis discussing what systemic therapy and for how long we should be treating patients with high-risk localized disease, M0 on conventional imaging but one bone lesion on PSMA PET/CT. Dr. De Santis started by commenting that there are several options for how to consider a patient with high-risk localized Disease, M0 on conventional imaging, but one bone lesion on PSMA PET/CT. The first option is to consider the patient localized high risk disease (cT1c, Gleason 8, PSA 7 ng/mL), which would place the patient in the inclusion criteria for the GETU-12 trial:

(UroToday.com) The 2023 European Association of Urology (EAU) annual congress held in Milan, Italy between March 10^th and 13^th, 2023 was host to a session addressing precision medicine in patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Elena Castro delivered a state-of-the-art lecture discussing mCRPC patient-related factors that guide treatment decisions.